Craven House Capital PLC Investee Companies' Update: Bio Vitos

RNS Number : 1196R

Craven House Capital PLC

05 June 2024

 

Craven House Capital PLC

5 June 2024

 

Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR") as applied in the United Kingdom. Upon publication of this Announcement, this information is now considered to be in the public domain.

Craven House Capital plc

("Craven House" or the "Company")

Investee Companies' Update: Bio Vitos

 

Further to the announcement on 28 November 2023, Craven House was allocated a pro-rata distribution of c.63,615,230 shares by Bio Vitos Medical Limited in Bio Vitos Pharma AB (previously known as Hemcheck Sweden AB). These shares amounted to a market value, at the time, of c.12 million Swedish Kroner / c.$1.136 US Dollars. 22,496,354 shares were sold to cover costs relating to the transaction. Following settlement of the transaction Craven House has received 41,118,876 shares in Bio Vitos Pharma AB, representing 15.4% of Bio Vitos Pharma AB's issued share capital.

Craven House remains a 24.5% shareholder in Bio Vitos Medical Limited and now owns 15.4% of Bio Vitos Pharma AB, a Sweden based medical technology company, listed on the Stockholm stock exchange.

For further information please contact:

Craven House Capital Plc Mark Pajak www.Cravenhousecapital.com	Tel: [phone]
SI Capital Broker Nick Emerson www.sicapital.co.uk	Tel: [phone]
SPARK Advisory Partners Limited Nominated Adviser Matt Davis www.Sparkadvisorypartners.com	Tel: [phone]

 About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDMZGGVNDMGDZM